Global bleeding Disorder
Therapeutics Market: Overview
Bleeding disorders usually
include symptoms in which delay in the blood clotting process can be observed.
Two main types of blood disorders include von Willebrand disease and
hemophilia, both of which are hereditary in nature. Von Willbrand is one of the
most common congenital bleeding disorders in humans, caused as a result of
deficiency of Von Willebrand factor (VWF) which assists in clot clotting
process. There are three types of Von Willebrand disorders classified on the
basis of level of VWF synthesis.
Read Report Overview - https://www.transparencymarketresearch.com/bleeding-disorder-therapeutics-market.html
Von Willebrand disorder’s
occurrence is almost equal in both sexes, and affects about 1% of the general
population according to the Centers for Disease Control and Prevention (CDC).
The most common complications of the disorder include heavy menstrual bleeding,
excessive gum bleeding and abnormal bleeding after minor injuries.
Hemophilia, on the other hand, is
a disorder in which clotting factors essential for clotting phenomenon are
inadequate or absent. In the U.S. about 400 newborns suffer from hemophilia
every year according to statistics published by the CDC. The two main types of
hemophilia are hemophilia A with deficiency of clotting factor VIII and
hemophilia B with deficiency of clotting factor IX. The National Heart, Lung
and Blood Institute, U.S. details that approximately 7 out of 10 individuals
who suffer from hemophilia A have severe form of the disorder.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12218
Global bleeding Disorder
Therapeutics Market: Drivers and Restraints
Although bleeding disorders
cannot be cured, various medications are directed to manage the symptoms of the
disorder. Medications may be prescribed before or after surgery, dental work or
after an injury to patients suffering from mild form of the disorder. Severe
form of the disorder can be controlled with daily medicines prescribed by the
doctor.
The market for bleeding disorder
therapeutics is driven by the large customer base, increased awareness about
the bleeding disorders and available cures, and favorable reimbursement
policies. The market will be seeded with new drugs emerging from a promising
pipeline. Moreover, patent expiry of existing brands will also provide generic
drug manufacturers opportunities to enter the lucrative bleeding disorder
therapeutics market.
Request for Analysis of COVID-19 Impact on Bleeding
Disorder Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=12218
Due to the high price of branded
drugs, the market for bleeding disorder therapeutics is mostly concentrated
towards western countries of North America and Europe. Low cost drugs will help
in better market penetration in under developed and developing economies where
patients cannot afford high cost of medical treatment. Hence availability of low cost generic drugs
will boost market growth in the countries of Asia-Pacific, Latin America,
Middle East and Africa.
Global bleeding Disorder
Therapeutics Market: Competitive Dynamics
A few drugs that have lost their
patent protection include NovoSeven by Novo Nordisk, whose patent expired in
Japan and in the U.S., in 2009 and November 2010, respectively, while the
European patent expired on a country-by-country basis in 2011, Plavix by
Bristol-Myers Squibb, Lovenox by Sanofi, Neupogen by Amgen, and Procrit by
Janssen. These drugs are now available in the market in generic cost effective
form.
Pre Book Bleeding Disorder Therapeutics Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=12218<ype=S
Companies are also trying to
discover gene therapy which can cure the disorder. Some of the players
conducting lineal trials are Biogen Idec, Novo Nordisk, Bayer Healthcare,
Xenetic Biosciences, Cangene Corporation, CSL Behring, Alnylam and Pfizer. The
global bleeding disorder therapeutics market is highly competitive and
fragmented. Technological advances will expand the boundaries of the market by
adding new products. In 2014, Baxter International, Inc. agreed to acquire
Chatham Therapeutics. The acquisition will give Baxter Chatham's developmental
gene therapy program which is directed toward of treatment of hemophilia.
More Trending Reports by Transparency Market Research –
Cholesterol Lowering Drugs Market: https://www.biospace.com/article/cholesterol-lowering-drugs-market-increase-in-prevalence-of-coronary-artery-disease-to-drive-market/
Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up
About Us
Transparency Market Research is a
global market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for several decision makers.
Our experienced team of analysts, researchers, and consultants use proprietary
data sources and various tools and techniques to gather and analyze
information.
Our data repository is
continuously updated and revised by a team of research experts so that it
always reflects latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and
secondary research techniques in developing distinctive data sets and research
material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free:
866-552-3453
